POTS & Dysautonomia Genetic Testing — postural orthostatic tachycardia syndrome is increasingly understood as part of a connective tissue–mast cell–autonomic triad, where genetic evaluation reveals the underlying biology driving treatment selection.
Whole genome sequencing evaluates connective tissue genes (COL5A1, TNXB, COL3A1), ion channel variants (SCN9A, SCN10A), mast cell genes (TPSAB1/hereditary alpha tryptasemia), and autonomic pathway genes — providing the genetic architecture underlying POTS and dysautonomia.
POTS & Dysautonomia — Genetic Testing
Postural orthostatic tachycardia syndrome (POTS) affects an estimated 1-3 million Americans, characterized by excessive heart rate increase upon standing (≥30 bpm or ≥120 bpm within 10 minutes) with orthostatic symptoms including lightheadedness, palpitations, presyncope, exercise intolerance, brain fog, and fatigue. POTS is not a single disease but a final common pathway of multiple underlying conditions — including connective tissue disorders, mast cell activation, small fiber neuropathy, autoimmune autonomic neuropathy, and primary autonomic dysfunction.
The EDS-POTS-MCAS triad (hypermobile Ehlers-Danlos syndrome, POTS, and mast cell activation syndrome) is increasingly recognized as a clinical entity. Up to 50% of hypermobile EDS patients have POTS, and up to 66% have mast cell activation features. Connective tissue laxity in blood vessel walls may allow excessive venous pooling, triggering compensatory tachycardia. Genetic variants in connective tissue genes (COL5A1, TNXB — tenascin-X deficiency, FLNB, COL3A1) and mast cell genes (TPSAB1 — hereditary alpha tryptasemia, KIT) contribute to this triad. SCN9A and SCN10A sodium channel variants affect small fiber nerve function and autonomic reflexes.
While POTS has traditionally been considered a functional or poorly understood condition, genetic evaluation is transforming it into a biologically characterized syndrome. Identification of connective tissue variants directs patients toward joint protection strategies, compression garments (addressing the vascular mechanism), and appropriate physical therapy approaches. Hereditary alpha tryptasemia (HαT, TPSAB1 duplication) identification guides mast cell-targeted therapy (antihistamines, mast cell stabilizers). SCN9A variants may guide sodium channel modulator therapy. This genetic subtyping of POTS represents an emerging precision medicine approach.
The EDS-POTS-MCAS triad is one of the most underdiagnosed genetic conditions in medicine. Patients see an average of 7 specialists before diagnosis. Genetic evaluation of connective tissue and mast cell genes can unify these seemingly unrelated symptoms.
POTS patients average 7 specialist visits before diagnosis. Genetic evaluation reveals the biological mechanism — EDS, mast cell activation, or autonomic neuropathy — directing treatment to the underlying cause rather than treating symptoms empirically.
Hereditary alpha tryptasemia (HαT) is found in ~5% of the general population — and is significantly enriched in POTS/MCAS patients
TPSAB1 duplication (hereditary alpha tryptasemia) causes elevated baseline serum tryptase and is associated with dysautonomia, flushing, GI dysmotility, and systemic reactions. HαT is significantly enriched in POTS and MCAS cohorts. Identification of HαT directs treatment toward mast cell stabilization (cromolyn, ketotifen) and antihistamine therapy — an approach that may not be considered without the genetic finding. WGS can evaluate TPSAB1 copy number alongside connective tissue gene analysis.
Connective tissue variant identification explains WHY compression garments work — and directs the rest of the POTS treatment plan
Identifying connective tissue gene variants (COL5A1, TNXB, FLNB) in a POTS patient provides the structural explanation for excessive venous pooling upon standing. This understanding guides treatment: compression garments (addressing vascular laxity), increased salt/fluid intake (expanding blood volume), targeted exercise (reconditioning deconditioned vasculature), and physical therapy focused on proprioception and joint protection. Without the connective tissue diagnosis, POTS treatment remains empirical rather than mechanism-targeted.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for POTS & Dysautonomia — Genetic Testing and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
